NCI-2022-05170

A Multicenter Open-Label Study of RMC-6236 in Patients with Advanced Solid Tumors Harboring Specific Mutations in RAS

This study is investigating a drug called RMC-6236 in patients with advanced solid tumors that have specific mutations in a gene called RAS. The study is being conducted at multiple centers and is open-label, meaning that both the patients and researchers know which treatment is being administered. The main objective of the study is to evaluate the safety and effectiveness of RMC-6236 in treating these advanced solid tumors with RAS mutations.

RAS: RAS mutations are alterations in certain genes controlling cell growth and division

For more information about the trial, click the link below:

https://clinicaltrials.gov/ct2/show/NCT05379985

Clinical Trial Site: Columbia

To see all available clinical trials click here.